Kodiak Sciences Inc (NASDAQ:KOD) has announced that its Phase 3 GLOW study evaluating tarcocimab tedromer 5 mg in moderately severe to severe NPDR met its one-year primary endpoint. The company has sufficient capital to further develop three clinical prospects. The GLOW study also met all key secondary endpoints, demonstrating a significant decrease in the risk of sight-threatening complications. Despite the positive news, KOD shares are down 14% at $2.03.